Blog Posts

Estela Rodriguez: A diagnostic shift from static biomarker quantification to assessing active immune pathways

Estela Rodriguez/X

Jan 30, 2025, 19:23

Estela Rodriguez: A diagnostic shift from static biomarker quantification to assessing active immune pathways

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared an article on X authored by Amanda Lindberg et al.:

“This study proposes a diagnostic shift from static biomarker quantification in pts with NSCLC to assessing active immune pathways to provide more precise ICI treatment. Ultimately, the results implicate a need for combination diagnostics and therapies.”

In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC.

Authors: Amanda Lindberg et al.

Amanda Lindberg Artur Mezheyeuski cancer Carina Strell Cecilia Lindskog Erika Broström Estela Rodriguez Hans Brunnström Hui Yu Jakob Friedrich Johan Botling Johan Isaksson Johanna Mattsson Klas Kärre Lars Muhl Louise Hellberg Max Backman Miklos Gulyas Neda Hekmati NSCLC OncoDaily Oncology Patrick Micke Rebecca Artursson

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?